Phathom Pharmaceuticals, Inc. (PHAT) fair value analysis
Nasdaq · Updated 2026-09-07
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines to treat gastrointestinal conditions. The company operates in the United States and other markets, focusing on bringing novel therapeutic options to patients with disorders of the digestive system.
Valuation status
Awaiting full valuationPHAT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $8.98
- Sector
- Healthcare
- 12-month range
- $8.98–$15.71
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for PHAT
- Shares are trading in the lower third of their 12-month price range of $8.98–$15.71.
- The 14-day relative strength index sits at a neutral 63.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PHAT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent PHAT news
TickrTrends' derived news-sentiment signal for PHAT is currently mixed, computed from recent coverage.
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (manilatimes.net, 2026-09-01)
TickrTrends take: Phathom Pharmaceuticals' participation in upcoming investor conferences provides an opportunity for the market to gain visibility into the company's strategic direction and pipeline progress, which are key factors in establishing a comprehensive valuation for the Healthcare sector company. With TickrTrends currently awaiting full valuation input on PHAT, investor conference presentations could supply additional operational and financial context that helps inform the company's market assessment. For valuation-focused observers, these conferences will be significant touchpoints for understanding PHAT's competitive positioning and near-term catalysts within the pharmaceutical industry. - Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PHAT) 2026-08-01 (seekingalpha.com, 2026-08-01)
TickrTrends take: Phathom Pharmaceuticals released its 2026 Q2 earnings presentation, providing updated financial performance data relevant to the company's Healthcare sector positioning. Given that TickrTrends' current assessment of PHAT remains at an awaiting full valuation status, investors focused on valuation metrics should examine the earnings call details for revenue trends, profitability developments, and cash position changes that could inform a more complete valuation framework. Key operational and financial metrics disclosed in the presentation would be essential data points for establishing a comprehensive valuation benchmark for the company.
What people are saying
Follow the PHAT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PHAT stock undervalued?
PHAT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is PHAT's TickrTrends verdict?
PHAT is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is PHAT overbought or oversold?
PHAT's 14-day RSI is in neutral territory - neither overbought nor oversold.